Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASH Clinical NewsThe POLARIX Study: Polatuzumab Vedotin w. Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) vs. R-CHOP Therapy in Patients w. Previously Untreated DLBCL

A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the first-line treatment of patients with DLBCL.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form